inactivated trivalent influenza vaccine (Sanofi)

The inactivated trivalent influenza vaccine (TIV) is a seasonal biological preparation designed to provide active acquired immunity against three strains of the influenza virus: two influenza A subtypes (typically H1N1 and H3N2) and one influenza B lineage. The vaccine contains inactivated (killed) viral particles or purified surface antigens, primarily the hemagglutinin (HA) glycoprotein. Upon administration, the immune system generates HA-specific neutralizing antibodies that prevent the virus from attaching to and infecting host cells. TIVs are traditionally produced using egg-based manufacturing processes and are indicated for the prevention of seasonal influenza. In the context of clinical trial NCT01623232, a standard-dose, unadjuvanted TIV (containing 15 µg of HA per strain) served as the control arm to evaluate the immunogenicity and safety of a MAS-1 adjuvanted reduced-dose formulation in adults aged 65 and older.

Brand names

FluzoneFluarixFluLavalAfluria

Other names

trivalent inactivated influenza vaccinetrivalent influenza vaccinesplit-virion influenza vaccine